Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Raltegravir Inclusion Decreases CD4 T-Cells Intra-Cellular Viral Load and Increases CD4 and CD28 Positive T-Cells in Selected HIV Patients.

Cells - 8 Jan 2022

Kumar Gaurav, Cottalorda-Dufayard Jacqueline, Garraffo Rodolphe, De Salvador-Guillouët Francine, Cua Eric, Roger Pierre-Marie

Abstract excerpt

Raltegravir (RLT) prevents the integration of HIV DNA in the nucleus, but published studies remain controversial, suggesting that it does not decrease proviral DNA. However, there are only a few studies focused on virus-targeted cells. We aimed our study on the impact of RLT inclusion on total intra-cellular viral DNA (TID) in cellular subsets and immune effects in patients with newly acquired undetectable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD28 Antigens
Share to CD4-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Viral

Share to HIV Infections

Share to Lymphocyte Count

Share to Monocytes

Share to Raltegravir Potassium

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 35053324
DOI: 10.3390/cells11020208
PMCID: PMC8773801

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Raltegravir Inclusion Decreases CD4 T-Cells Intra-Cellular Viral Load and Increases CD4 and CD28 Positive T-Cells in Selected HIV Patients.PMID 35053324Read ↗

HIV-1 DNA dynamics and variations in HIV-1 DNA protease and reverse transcriptase sequences in multidrug-resistant patients during successful raltegravir-based therapy.Semantic proximity Read ↗

HIV-1 persistence during ARTSemantic proximity Read ↗

Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological successSemantic proximity Read ↗

Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwardsSemantic proximity Read ↗

Total HIV DNA: a global marker of HIV persistenceSemantic proximity Read ↗

Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levelsSemantic proximity Read ↗

A higher CD4/CD8 ratio correlates with an ultralow cell-associated HIV-1 DNA level in chronically infected patients on antiretroviral therapy: a case control studySemantic proximity Read ↗

Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integrationSemantic proximity Read ↗

Low-level HIV-1 viremia affects T-cell activation and senescence in long-term treated adults in the INSTI eraSemantic proximity Read ↗

Quantification of Total HIV DNA as a Marker to Measure Viral Reservoir: Methods and Potential Implications for Clinical PracticeSemantic proximity Read ↗

Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection.Semantic proximity Read ↗

Measuring integrated HIV DNA ex vivo and in vitro provides insights about how reservoirs are formed and maintainedSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.